Cost-effectiveness and socioeconomic implications of prevention and management of chronic kidney disease in type 2 diabetes

Nephrology

Volumn 15, Issue SUPPL. 1, 2010, Pages

  Chadban, S ^a   Howell, M ^a   Twigg, S ^a   Thomas, M ^a   Jerums, G ^a   Cass, A ^a   Campbell, D ^a   Nicholls, K ^a   Tong, A ^a   Mangos, G ^a   Stack, A ^a   MacIsaac, R J ^a   Girgis, S ^a   Colagiuri, R ^a   Colagiuri, S ^a   Craig, J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; PLACEBO;

ALBUMINURIA; BLOOD GLUCOSE MONITORING; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG COST; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH SERVICE; HIGH RISK POPULATION; HUMAN; HYPERTENSION; INDIGENOUS PEOPLE; KIDNEY BIOPSY; KIDNEY FAILURE; LIFE EXPECTANCY; LIFESTYLE MODIFICATION; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT REFERRAL; PRIORITY JOURNAL; REIMBURSEMENT; RESOURCE MANAGEMENT; REVIEW; RISK FACTOR; SOCIOECONOMICS; ARTICLE; CHRONIC DISEASE; CHRONIC KIDNEY FAILURE; COST BENEFIT ANALYSIS; DIABETIC NEPHROPATHY; PRACTICE GUIDELINE; SOCIAL CLASS;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HUMANS; KIDNEY FAILURE, CHRONIC; SOCIAL CLASS;

EID: 77950488259     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2010.01241.x     Document Type: Review

References (47)

1. Palmer AJ, Valentine WJ, Chen R et al. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA. Nephrol. Dial. Transplant. 2008 23 : 1216 1223.
2. Australian and New Zealand Dialysis and Transplant Registry. ANZDATA Registry Report 2007; 30th Annual Report Cited Feb 2009.] Available from URL: http://www.anzdata.org.au/v1/report-2007.html
3. Cass A, Chadban S, Craig J et al. The Economic Impact of End-Stage Kidney Disease in Australia. Kidney Health Australia, Melbourne, 2006 [available at http://www.kidney.org.au ].
4. Craig JC, Barratt A, Cumming R et al. Feasibility study of the early detection and treatment of renal disease by mass screening. Intern. Med. J. 2002 32 : 6 14. (Pubitemid 36124631)
5. O'Brien JA, Shomphe LA, Kavanagh PL et al. Direct medical costs of complications resulting from type 2 diabetes in the U.S. Diabetes. Care. 1998 21 : 1122 1128.
6. Eastman RC, Javitt JC, Herman WH et al. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes. Care. 1997 20 : 735 744.
7. The HOPE Study Group. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000 355 : 253 259.
8. Strippoli GF, Craig M, Craig JC. Antihypertensive agents for preventing diabetic kidney disease. Cochrane. Datab. Syst. Rev. 2005 4 : CD004136.
9. Strippoli GF, Bonifati C, Craig M et al. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane. Datab. Sys. Rev. 2006 4 : CD006257.
10. Boersma C, Atthobari J, Gansevoort RT et al. Pharmacoeconomics of angiotensin II antagonists in type 2 diabetic patients with nephropathy: Implications for decision making. Pharmacoeconomics. 2006 24 : 523 535.
11. UKPDS. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ. 1998b 317 : 713 720.
12. Fulcher GR, Conner GW, Amerena JV. Prevention of cardiovascular disease: An evidence-based clinical aid. Med. J. Aust. 2004 181 : F1 F14.
13. Ravid M, Savin H, Jutrin I et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann. Intern. Med. 1993 118 : 577 581.
14. Ravid M, Brosh D, Levi Z et al. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann. Intern. Med. 1998a 128 : 982 988.
15. Adler NE, Ostrove JM. Socioeconomic status and health: What we know and what we don't. Ann. NY. Acad. Sci. 1999 896 : 3 15.
16. Bello AK, Peters J, Rigby J et al. Socioeconomic status and chronic kidney disease at presentation to a renal service in the United Kingdom. Clin. J. Am. Soc. Nephrol. 2008 3 : 1316 1323.
17. Dunstan DW, Zimmet PZ, Welborn TA et al. The rising prevalence of diabetes and impaired glucose tolerance: The Australian Diabetes, Obesity and Lifestyle Study. Diabetes. Care. 2002 25 : 829 834.
18. Tapp RJ, Shaw JE, Zimmet PZ et al. Albuminuria is evident in the early stages of diabetes onset: Results from the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Am. J. Kid. Dis. 2004 44 : 792 798.
19. Cass A, Cunningham J, Snelling P et al. Exploring the pathways leading from disadvantage to end-stage renal disease for indigenous Australians. Soc. Sci. Med. 2004 58 : 767 785.
20. Guest CS, Ratnaike S, Larkins RG. Albuminuria in aborigines and Europids of south-eastern Australia. Med. J. Aust. 1993 159 : 335 338.
21. Hoy W. Renal disease in Australian Aborigines. Nephrol. Dial. Transplant. 2000 15 : 1293 1297.
22. McGill MJ, Donnelly R, Molyneaux L et al. Ethnic differences in the prevalence of hypertension and proteinuria in NIDDM. Diab. Res. Clin. Prac. 1996 33 : 173 179.
23. Preston-Thomas A, Cass A, O'Rourke P. Trends in the incidence of treated end-stage kidney disease among Indigenous Australians and access to treatment. ANZ. J. Pub. Health. 2007 31 : 419 421.
24. Spencer JL, Silva DT, Snelling P et al. An epidemic of renal failure among Australian Aboriginals. Med. J. Aust. 1998 168 : 537 541.
25. McDonald SD, Russ GR. Burden of end-stage renal disease among indigenous peoples in Australia and New Zealand. Kidney. Int. 2003 63 : S123 S27.
26. McDonald SD, Russ GR. Current incidence, treatment patterns and outcome of end-stage renal disease among indigenous groups in Australia and New Zealand. Nephroology. 2003 8 : 42 8.
27. Cass A, Cunningham J, Hoy W. The relationship between the incidence of end-stage renal disease and markers of socioeconomic disadvantage. NSW. Pub. Health. Bull. 2002 13 : 147 151.
28. Anderson K, Devitt J, Cunningham J et al. 'All they said was my kidneys were dead': Indigenous Australian patients' understanding of their chronic kidney disease. Med. J. Aust. 2008 189 : 499 503.
29. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. V 5.0.0. The Cochrane collaboration 2008 Cited April 2008.] Available from URL: http://www.cochrane-handbook.org
30. UKPDS. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group. BMJ. 1998a 317 : 720 726.
31. Gray A, Clarke P, Raikou M et al. An economic evaluation of atenolol vs. captopril in patients with Type 2 diabetes (UKPDS 54). Diabetic. Med. 2001 18 : 438 444.
32. Kasiske BL, Kalil RS, Ma JZ et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis. Ann. Intern. Med. 1993 118 : 129 138.
33. Weidmann P, Schneider M, Bohlen L. Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: An updated meta-analysis. Nephrol. Dial. Transplant. 1995 10 (Suppl 9 39 45.
34. Howard K, Salkeld G, White S et al. The Cost-Effectiveness of Early Detection and Intervention to Prevent the Progression of Chronic Kidney Disease in Australia. Kidney Health Australia, Melbourne, 2006 available at: http://www.kidney.org.au/ L, Birkmeyer JD, Welch HG. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann. Intern. Med. 1999 131 : 660 667.
35. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensin- converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Eng. J. Med. 1993 329 : 1456 1462.
36. Hasslacher C, Ritz E, Wahl P et al. Similar risks of nephropathy in patients with type I or type II diabetes mellitus. Nephrol. Dial. Transplant. 1989 4 : 859 863.
37. Siegel JE, Krolewski AS, Warram JH et al. Cost-effectiveness of screening and early treatment of nephropathy in patients with insulin-dependent diabetes mellitus. J. Am. Soc. Nephrol. 1992 3 (Suppl 4 S111 S19.
38. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Eng. J. Med. 2001 345 : 870 878.
39. White SL, McGeechan K, Jones M et al. Socioeconomic disadvantage and kidney disease in the United States, Australia, and Thailand. Am. J. Public. Health. 2008 98 : 1306 1313.
40. Weng C, Coppini DV, Sonksen PH. Geographic and social factors are related to increased morbidity and mortality rates in diabetic patients. Diabetic. Medicine. 2000 17 : 612 617.
41. Drey N, Roderick P, Mullee M et al. A population-based study of the incidence and outcomes of diagnosed chronic kidney disease. Am. J. Kid. Dis. 2003 42 : 677 684.
42. Tarver-Carr ME, Powe NR, Eberhardt MS et al. Excess risk of chronic kidney disease among African-American versus white subjects in the United States: A population-based study of potential explanatory factors. J. Am. Soc. Nephrol. 2002 13 : 2363 2370.
43. Davis TM, McAullay D, Davis WA et al. Characteristics and outcome of type 2 diabetes in urban Aboriginal people: The Fremantle Diabetes Study. Intern. Med. J. 2007 37 : 59 63.
44. Chan MR, Dall AT, Fletcher KE et al. Outcomes in patients with chronic kidney disease referred late to nephrologists: A meta-analysis. Am. J. Med. 2007 120 : 1063 1070.
45. Cass A, Cunningham J, Snelling P et al. Urban disadvantage and delayed nephrology referral in Australia. Health. &. Place. 2003 9 : 175 182.
46. Overland J, Hayes L, Yue DK. Social disadvantage: Its impact on the use of Medicare services related to diabetes in NSW. ANZ. J. Public. Health. 2002 26 : 262 265.
47. Turrell G, Oldenburg BF, Harris E et al. Utilisation of general practitioner services by socioeconomic disadvantage and geographic remoteness. ANZ. J. Public. Health. 2004 28 : 152 158.